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Summary
A series of benzo-macrolactones of varying ring size
and conformation has been prepared by chemical syn-
thesis and evaluated by structural and biological tech-
niques. Thus, 12- to 16-membered lactones were ob-
tained by concise routes, involving ring-closing
metathesis as a key step. In enzyme assays, the 13-,
15-, and 16-membered analogs are good inhibitors,
suggesting that they can adopt the required conforma-
tion to fit in the ATP-binding site. This was confirmed
by cocrystallization of 13-, 14-, and 15-membered lac-
tones with the N-terminal domain of yeast Hsp90,
showing that they bind similarly to the ‘‘natural’’ 14-
membered radicicol. The most active compounds in
the ATPase assays also showed the greatest growth-
inhibitory potency in HCT116 human colon cancer
cells and the established molecular signature of
Hsp90 inhibition, i.e., depletion of client proteins
with upregulation of Hsp70.
*Correspondence: c.j.moody@nottingham.ac.ukIntroduction
Heat shock protein 90 (Hsp90) is one of the most abun-
dant proteins in eukaryotic cells and is an ATP-depen-
dent chaperone that plays a central role in regulating
the stabilization, activation, and degradation of a range
of proteins [1–3]. These ‘‘clients’’ include a number of
key proteins involved in cell cycle regulation and signal
transduction (see http://www.picard.ch/downloads/
Hsp90interactors.pdf). Furthermore, among Hsp90’s cli-
ent proteins are a number of known overexpressed or
mutant oncogenic proteins such as C-RAF, B-RAF,
ERBB2, AKT, telomerase, and p53, many of which are
associated with the six hallmarks of cancer [4, 5]. Con-
sequently, Hsp90 has become an attractive target for
novel cancer therapeutic agents, since its inhibition
will disrupt multiple cancer-causing pathways simulta-
neously [4, 6–10]. Recently, it has been suggested that
targeting Hsp90 may also halt neurodegeneration [11].
The Hsp90 proteins possess a conserved ATP-bind-
ing pocket in the N-terminal domain [12, 13], and it is dis-
ruption of ATP binding (and subsequent hydrolysis) that
leads to proteasomal degradation of client proteins [14].
Most inhibitors of Hsp90 bind to the N-terminal ATP site
[15, 16], although the naturally occurring antibiotic novo-
biocin is known to bind at the C terminus and is therefore
also of interest [17–19]. Known inhibitors include the
natural products radicicol, 1, and geldanamycin, 2,
both of which have been cocrystallized with the yeast
protein; the protein-bound structures of 1 and 2 were
determined by X-ray crystallography [15]. The binding
of both radicicol, 1, and geldanamycin, 2, to the protein
has also been studied in solution by NMR spectroscopy
[20]. A derivative of geldanamycin, 17-allylamino-17-
desmethoxygeldanamycin (17-AAG), 3, is the first-in-
class inhibitor of Hsp90 to enter the clinic and is now
in phase II trial [21, 22]. Several unnatural (designed),
synthetic inhibitors are ATP mimics and are based on
the purine framework, as exemplified by PU3, 4a, and
PU24FC1, 4b, and by the closely related arylsulfanyl
compound PU-H58, 5 [23–28]. However, other families
of inhibitors are now emerging, in particular the 3-(2,4-
dihydroxyphenyl)pyrazoles [29], as in CCT018159, 6a
[30, 31], G3130, 6b [32], and VER-49009, 6c [33, 34],
while members of the most recently discovered family
contain the 1-aryl-2-naphthol moiety as in compound 7
[35] (Figure 1).
Of these inhibitors (Figure 1), radicicol, 1 (also known
as monorden), originally isolated from the fungus Mono-
cillium nordinii [36], and subsequently from both Nectria
radicicola [37] and from the plant-associated fungus
Chaetomium chiversii [38], is the most potent in vitro
[39], although it has little or no activity in vivo [40, 41].
This is presumably a result of its instability, particularly
toward conjugate addition to the dienone moiety, al-
though its oxime derivative did possess some in vivo ac-
tivity [42]. The natural product itself has attracted the in-
terest of synthetic chemists and has been the subject of
three total syntheses by the groups of Lett [43–46], Dan-
ishefky [47], and Winssinger [48]. In a search for further
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1204Figure 1. Structures of Hsp90 Inhibitorsbiologically active analogs, Danishefsky and coworkers
have developed a novel series of inhibitors based on
cycloproparadicicol [49–51]. These molecules, obtained
by quite lengthy chemical synthesis, show promising ac-
tivity and demonstrate that modified synthetic analogs of
radicicol do have potential as anticancer compounds.
Further work in this area [52–57], including a very recent
study that attempts to identify the key features of the 14-
membered ring of radicicol that are necessary for biolog-
ical activity [38], has been reported of late.
The aim of the present study is the design and chem-
ical synthesis of a series of radicicol analogs of different
ring size, and hence conformation; the characterization
of their binding to Hsp90 by protein crystallography
and molecular modeling; and their biological evaluation.
The results of this integrated chemistry/biology ap-
proach are described herein.
Results and Discussion
The starting point for our work was a reconsideration of
the detailed structure of radicicol, 1, bound in the ATP
pocket in the N-terminal domain of yeast Hsp90 [15],
particularly in light of the more recent biological data
on radicicol analogs [49–51]. The yeast and human en-
zymes exhibit 88% similarity (70% identity) between
their N-terminal domains. Within 5 A˚ of bound ADP,
there are only two differences between the yeast and hu-
man proteins, namely, Ala38 (human Ser52) and Leu173
(human Val186), which are approximately 4 and 5 A˚, re-
spectively, from the exocyclic N6 of the adenine ring of
ADP. Consequently, all of the key interactions with
ADP, ATP, and various Hsp90 inhibitors such as gelada-
mycin and radicicol are essentially the same. The crystalstructure of radicicol, 1, bound to yeast Hsp90 (Fig-
ure 2A) shows that the antibiotic adopts a folded confor-
mation and that the key hydrogen-bonding interactions
involve the salicylate ester and phenolic groups with
water molecules. Most importantly, the carboxylate
side chain of Asp79, the main chain amide group of
Gly83, and the hydroxyl side chain of Thr171 interact
with radicicol via the same tightly bound water mole-
cule. Another interaction occurs between the main chain
carbonyl of Leu34 and radicicol, via another water mol-
ecule. Although the structure clearly shows the involve-
ment of the epoxide oxygen in hydrogen bonding to the
3-amino side chain of Lys44, the relatively minimal 2-fold
loss of in vitro activity in the corresponding cyclopro-
pane suggests that this interaction, although useful, is
not essential [49].
Therefore, we decided on a series of compounds that
not only lacked this epoxide, but also the sensitive dien-
one fragment. We also decided to simplify the structures
further by removing the remaining stereocenter by in-
vestigating compounds lacking the methyl group a to
the macrolactone oxygen. However, our major objective
was the synthesis and evaluation of smaller and larger
ring sizes, since the conformation of the 14-membered
macrolactone is thought to have an important influence
on binding to Hsp90 [55], and hence the biological activ-
ity of radicicol analogs. It is the structural and biological
evaluation of different ring sizes resulting in varying con-
formations of the radicicol analogs that distinguishes
our work from that previously published.
Chemical Synthesis
The synthetic routes for the novel radicicol analogs
start with the known benzoic acid derivative, 8, an
Inhibition of Hsp90 with Synthetic Macrolactones
1205Figure 2. Binding Interactions of Macrolactone Inhibitors with Yeast Hsp90
(A–E) In all cases, the hydrogen-bonded interactions in the ATP-binding site are represented as broken lines. (A) Radicicol, 1 (data taken from
[15]; data are available at PDB ID: 1BGQ). (B) 14-membered lactone, 15a (PDB ID: 2CGF). (C) 13-membered lactone, 15f cis (PDB ID: 2IWS). (D)
13-membered lactone, 15f trans (PDB ID: 2IWU). (E) 15-membered lactone, 15h (PDB ID: 2IWX).intermediate in Danishefsky and coworkers’ first-gener-
ation synthesis of radicicol [47]. Mitsunobu esterification
with 3-butenol gave benzoate, 9a, in which the chloride
was displaced by the anion derived from 2-(5-hexenyl)-
1,3-dithiane, 10a, to give 11a. Protection of the phenol
as its tert-butyldimethylsilyl (TBDMS) ether, 12a, was fol-
lowed by the ring-closing metathesis (RCM) reaction to
generate the macrocycle, a tactic commonly used in re-
lated syntheses [47, 48, 50, 57, 58]. Thus, use of the
Grubbs second-generation catalyst, benzylidene(1,3-bis[2,4,6-trimethylphenyl]-2-imidazolidinylidene)dichloro-
(tricyclohexylphosphine)ruthenium, gave the 14-mem-
bered ring 13a. Deprotection of the thioketal and silyl
ethers by using bis(trifluoroacetoxy)iodobenzene [59]
and tetra-n-butylammonium fluoride (TBAF), respec-
tively, gave resorcinol, 14a, chlorination of which gave
the desired chloride, 15a (Figure 3). The sequence was
repeated by using racemic, (S)-4-penten-2-ol, and (R)-
4-penten-2-ol to give the corresponding racemic, (R)-
14-membered, and (S)-14-membered rings, 15b, 15c,
Chemistry & Biology
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(A) Synthesis of resorcinol-type derivatives; DIAD = di-isopropyl azodicarboxylate.
(B) Synthesis of resorcinol dimethyl ethers.
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1207Figure 4. X-Ray Crystal Structures, Showing Crystallographic Numbering, of Macrolactones
(A) 14-membered ring 14b.
(B) 13-membered ring 14f.
(C) 12-membered ring 15g.
(D) 14-membered ring 23.and 15d, respectively, as shown in Figure 3. The stereo-
chemistry of the alkene formed in the RCM reaction was
established as trans (E) by an X-ray crystallographic
analysis of the macrocycle 14b (Figure 4A) that shows
the intramolecular hydrogen bond of salicylate ester.
The position of chlorination was established by using
NMR spectroscopy.
Our synthetic route is extremely versatile, and via
changes in the chain length of the starting alcohol or in
the 2-alkenyl-1,3-dithiane, 10, one can readily access
a wide range of compounds. Hence it is possible to in-
vestigate binding of synthetic analogs of different con-
formations, such as the 14-membered ring with the dou-
ble bond in a different position (15e), both the cis and
trans 13-membered rings (15f), the 12-membered ring
(15g), the 15-membered rings (15h and 15i), and the 16-
membered ring (15j), to the ATP-binding site of Hsp90.
The preparation of these analogs is summarized in
Figure 3A. Wherever possible, the alkene geometry
was confirmed by X-ray crystallography as shown for
the cis 13-membered ring intermediate, 14f, and the
trans 12-membered ring, 15g (Figures 4B and 4C), or
by NMR spectroscopy (trans J= 12–15 Hz;cis J=w7 Hz).Alkenes 15a and 15b were converted into the corre-
sponding epoxides, 16a and 16b, by reaction with 3-
chloroperoxybenzoic acid, and 15b was also reduced
to the corresponding alkane, 17. The 15-membered
ring 14h was also brominated (NBS), rather than chlori-
nated, although the product was the dibromide, 18, as
opposed to the expected monobromide. The flexible
open-chain diene, compound 19, was prepared from
12c as shown in Figure 3A. Finally, the dimethoxy com-
pounds 25 and 26 were also prepared for comparison
purposes from the known benzoic acid, 20 [47]; the trans
alkene was again confirmed by X-ray crystallographic
analysis of the dithiane intermediate, 23 (Figures 3B
and 4D).
Protein Crystallography
The macrocycle, 15a, was cocrystallized with the N-ter-
minal domain of yeast Hsp90, and the structure of the re-
sulting complex was solved by molecular replacement.
The structure (Figure 2B) shows that the compound
binds in a similar way to radicicol, and that it retains
the key water molecules in the H-bonding network.
However, the direct interaction with the 3-amino side
Chemistry & Biology
1208Figure 5. Molecular Modeling
(A) Overlaid structures of protein-bound con-
formations of radicicol (blue) and synthetic
macrolactone, 15a (red).
(B) Overlaid structures of protein-bound
conformations of synthetic macrolactones:
14-membered lactone, 15a (red), 13-mem-
bered lactone, 15f cis (yellow), 13-mem-
bered lactone, 15f trans (green), and 15-
membered lactone, 15h (blue).chain of Lys44 is replaced by hydrophobic interactions
with 15a due to the loss of the epoxide oxygen. A com-
mon set of hydrophobic interactions between the pro-
tein and the inhibitors, 15a and 1, are also seen
(Asn37, Asp40, Ile82, Met84, Phe124 and Leu173), and
Ala41 is also involved in a hydrophobic interaction with
15a. Likewise, both cis and trans 13-membered rings,
15f cis and 15f trans, respectively, and the 15-mem-
bered ring 15h were cocrystallized with the N-terminal
domain of yeast Hsp90. The structures are shown in Fig-
ures 2C–2E, and they essentially bind in the same way as
15a. However, there is an additional hydrogen-bond in-
teraction between the side chain of Asn92 and the O5
oxygen of 15h. The structures for 15f cis and 15h, with
drastically different ring sizes and conformations, are
accommodated within the hydrophobic surface that is
the same as that which interacts with radicicol, 1, and
there are no significant alterations in the ATP-binding
site that result from interactions with 15f cis and 15h.
The data collected for 15f trans were substantially
weaker than those for 15f cis (average I/sI, 7.4; cf.
17.3). Consequently, the refinement was not as straight-
forward, leading to higher R and Rfree values for this
structure, even though the density for the inhibitor was
clear. For this reason also, only the most tightly bound
water molecules were located in the difference maps.
With X-ray data available, it was possible to conduct
modeling experiments to compare the bound conforma-
tion of radicicol and the simplified analog, 15a. The
structures of both 15a and radicicol within Hsp90 were
energy minimized by using the Monte Carlo method
(MOE software). By combination of the resulting struc-
tures, it was observed that the protein fragments overlay
almost perfectly. The protein was then masked to simul-
taneously show the conformation of 15a and radicicol,
which exhibited a high degree of similarity. The results
are shown in Figure 5A. Likewise, it was possible to
overlay the protein-bound conformations of the14-
membered lactone, 15a, with the cis and trans 13-mem-
bered rings, 15f, and the15-membered lactone, 15h, as
shown in Figure 5B. While the 14- and 15-membered
rings adopt similar conformations, the two 13-mem-
bered rings are different, both from each other and
from the two higher ring sizes, highlighting the ability
of the ATP site to accommodate the varying ring sizes
and conformations presented by these analogs. Isother-
mal titration calorimetry confirmed that 15a, 15f cis, 15ftrans, and 15h bound with similar affinity to intact yeast
Hsp90 (Kd = 0.39, 0.44, 1.2, and 0.21 mM, respectively;
results not shown), though with a higher Kd than radici-
col (Kd = 0.007 mM).
Biological Evaluation
The novel compounds were evaluated in the malachite
green assay for Hsp90 ATPase activity [60], and also
by using a fluorescence polarization (FP) assay [33,
61]. As shown previously, the more sensitive FP assay
gives IC50 values about 5–10 times lower than the AT-
Pase assay [33, 61]. The results are shown in Table 1.
It is immediately apparent that many of these ‘‘stripped
down’’ 14-membered ring analogs of radicicol retain
considerable biological activity; the simplest analog,
15a, and its racemic methyl homolog, 15b, are only 3-
to 8-fold less potent than the structurally more complex
natural product. As expected, the ‘‘natural’’ (R)-methyl
compound, 15c, is more potent than the racemate,
15b, and it is only 2-fold less potent than radicicol in
the FP assay. The ‘‘unnatural’’ (S)-isomer, 15d, is less
potent than the racemate. The epoxides 16a and 16b
have similar potency to their alkene precursors, and
while the deschloro compound 14c retains some activ-
ity, the dibromide, 18, is less potent. Both the alkane,
17, and the flexible open-chain diene, 19, are w20-fold
less active than their cyclic alkene counterparts, while
compound 15e with the double bond in a different posi-
tion is significantly less active, demonstrating the effect
of the double bond on the conformation of the macro-
cycle. Not surprisingly, removal of the H-bonding capac-
ity of the phenolic groups, as in the dimethoxy com-
pounds 25 and 26, results in almost complete loss of
activity.
Our versatile synthetic chemistry also provided ac-
cess to 12-, 13-, 15-, and 16-membered ring analogs
for comparison with the ‘‘natural’’ 14-membered ring
compounds. Of these, the cis and trans 13-membered
rings, 15f, were slightly less active than their 14-mem-
bered homolog, and despite their differing conforma-
tions, they have similar activity to each other (w0.5 mM
in the FP assay); the 12-membered ring 15g is less po-
tent still (w4 mM). While the 15-membered rings 15h
and 15i (0.1–0.2 mM) essentially retain the same activity
as its 14-membered analog, 15a (0.11 mM), the 16-mem-
bered ring 15j (>0.2 mM) is slightly less potent. Unfortu-
nately, although the 14-membered ring 15a could be
Inhibition of Hsp90 with Synthetic Macrolactones
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Entry Compound Structure FP Assay, IC50 (mM) ATPase Assay, IC50 (mM) SRB Assay, IC50 (mM)
1 1 0.047, 0.03 0.2 0.025, 0.068
2 15a 0.12, 0.10 <1, 1.3 3.2, 2.9
3 16a 0.19, 0.31 2.1, 2.5 5.5, 6.4
4 15b 0.16, 0.31 1, 1.5 12, 17
5 16b 0.31, 0.25 1.9, 2.2 1.8, 2.6
6 17 1.29, 3.23 23, 34 33, 66
7 25 38.2, 24.0 >100, >100 16, 28
8 26 58.4 >100, >100 42, 88
9 14c 0.54, 0.50 4, 3.2 23, 22
10 15c 0.10, 0.10 <1, 1 4.7, 7.2
11 15d 3.4, 5.4 >10 76, 68
12 19 2.1, 2.9 16, 27 29, 27
(Continued)
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Entry Compound Structure FP Assay, IC50 (mM) ATPase Assay, IC50 (mM) SRB Assay, IC50 (mM)
13 15e 1.9, 1.9 10 35, 33
14 15f cis 0.50, 0.85 2.4 22, 14
15 15f trans 0.59, 1.0 3.5 10, 8.6
16 15g 4.18, 3.8 13 48, 60
17 15h 0.16, 0.10 0.76 6, 15
18 15i 0.22, 0.16 4.9, 4.3 20
19 18 2.63, 1.1 — 40, 64
20 15j 0.24, 0.87 — 38, 48obtained as a pure (E)-alkene isomer, both the 15- and
16-membered rings contained a small amount (5%–
15%) of the (Z)-alkene isomer.
The most potent compounds in the FP and ATPase
assays also show the greatest growth-inhibitory po-
tency in the HCT116 human colon cancer cell line, as
measured by the SRB assay. Compounds showing the
greatest cell growth-inhibitory activity were those that
were most potent against the Hsp90 enzyme, including
15a, 16a, 16b, and 15c. It should be pointed out, how-
ever, that the difference between potency in the FP as-
say and that in cells is much greater for the potent syn-
thetic compounds (e.g., 15b or 16b) than for radicicol.
Also, when comparing 15b and 16b, it is clear that the
difference in cellular potency between these com-
pounds correlates only poorly with their activity in the
FP assay. It is reasonable to speculate that these dis-
crepancies may be due to differences in cell uptake. It
is possible that the natural product radicicol benefits
from a cellular uptake mechanism that cannot be ac-
cessed by the current synthetic inhibitors. To confirmthat growth inhibition was due to the intended mecha-
nism, we assessed compounds 15a, 15c, and 15h for
their effect on the established molecular signature of
Hsp90 inhibition [3]. Figure 6 shows depletion of client
proteins C-RAF, ERBB2, and CDK4, together with upre-
gulation of Hsp70, thus confirming that the new, to our
knowledge, analogs were acting as Hsp90 inhibitors in
the cell. No effect was seen with the essentially inactive
analog, 26.
Significance
Structural analysis of the Hsp90-radicicol complex has
facilitated the design of a series of analogs of the 14-
membered ring macrocyclic lactone natural product,
and the different ring sizes and conformations have al-
lowed us to investigate the ability of the ATP-binding
site to accept such radicicol analogs. These novel an-
alogs retain potent binding and inhibitory activity
against the ATPase activity of Hsp90. They are struc-
turally much less complex than radicicol and, hence,
Inhibition of Hsp90 with Synthetic Macrolactones
1211are readily accessible by chemical synthesis. Of par-
ticular interest is the high activity of ‘‘unnatural’’ ring
sizes such as the 15-membered ring homolog. Protein
crystallography has shown that the ATP site unexpect-
edly can readily accommodate analogs of differing
ring sizes and conformations. Biological studies dem-
onstrated that growth-inhibitory activity against hu-
man colon cancer cells was due to Hsp90 inhibition
by confirming client protein depletion and Hsp70
upregulation.
Experimental Procedures
Chemistry
Characterization data for final products are described below.
(R)-2,4-Dihydroxy-7-methyl-7,8,11,12,13,14-hexahydro-6-oxa-
16H-benzocyclotetradecene-5,15-dione 14c
mp 172C 2174C; [a]23D 2 98.0 (c 1.00, CHCl3); (Found: C, 67.5; H,
7.0. C18H22O5 requires C, 67.9; H, 7.0%); (Found: M
+, 318.1467.
C18H22O5 requires 318.1454); nmax (KBr)/cm
21 3391, 2943, 2923,
1688, 1654; dH (300 MHz; CDCl3) 11.96 (1 H, s, OH), 7.38 (1 H, s,
OH), 6.37 (1 H, d, J 1.9, ArH), 6.16 (1 H, d, J 1.9, ArH), 5.53–5.30 (3
H, m, CH=CH, OCHMe), 4.00 (2 H, AB, J 16.6, ArCH2), 2.64–1.40
(10 H, m, 5 3 CH2), 1.40 (3 H, d, J 6.4, Me); dC (75 MHz; CDCl3)
210.8, 170.6, 165.7, 160.2, 139.0, 135.1 (CH), 124.6 (CH), 112.2
(CH), 105.5, 102.9 (CH), 72.9 (CH), 49.8 (CH2), 40.8 (CH2), 37.7
(CH2), 32.5 (CH2), 25.1 (CH2), 22.2 (CH2), 19.0 (Me); m/z (FI) 318
(M+, 10%), 133 (13), 108 (35).
(E)-1-Chloro-2,4-dihydroxy-7,8,11,12,13,14-hexahydro-6-oxa-
16H-benzocyclotetradecene-5,15-dione 15a
mp 168C 2169C; (Found: C, 60,0; H, 5.6. C17H19ClO5 requires C,
60.3; H, 5.65%); (Found: M+, 338.0916. C17H19
35ClO5 requires
338.0921); nmax (KBr)/cm
21 3241, 2927, 2863, 1699, 1654, 1240; dH
(300 MHz; CDCl3) 11.81 (1 H, s, OH), 6.58 (1 H, s, ArH), 6.50 (1 H, s,
OH), 5.56–5.37 (2 H, m, CH=CH), 4.43 (2 H, t, J 5.4, OCH2), 4.28 (2
H, s, ArCH2), 2.58 (2 H, t, J 6.4, CH2CO), 2.40–2.40 (2 H, m, CH2),
2.12–2.08 (2 H, m, CH2), 1.74–1.66 (2 H, m, CH2), 1.59–1.53 (2 H, m,
CH2); dC (75 MHz; CDCl3) 207.0, 171.0, 163.7, 156.4, 136.1 (C) 134.0
(CH), 126.1 (CH), 114.7, 107.0, 103.5 (CH), 65.5 (CH2), 46.7 (CH2),
40.9 (CH2), 32.2 (CH2), 31.5 (CH2), 25.5 (CH2), 22.0 (CH2); m/z (FI)
340/338 (M+, 41/100%), 304 (5).
Figure 6. Western Blot Showing Depletion of Client Proteins C-
RAF, ERBB2, and CDK4, with Upregulation of Hsp70, upon Treat-
ment with Radicicol and Macrolactones
GAPDH was used as a loading control. HCT116 cells treated with
5 3 IC50 of compound. The dimethoxy analog, 26, which is essen-
tially inactive (IC50 > 50 mM), was tested at 65 mM.(R)-1-Chloro-2,4-dihydroxy-7-methyl-7,8,11,12,13,14-
hexahydro-6-oxa-16H-benzocyclotetradecene-5,15-dione 15c
mp 130C2132C; [a]23D 2 22.0 (c 1.00, CHCl3); (Found: M
+, 352.1073.
C18H21
35ClO5 requires 352.1078); nmax (KBr)/cm
21 3320, 2934, 2856,
1704, 1651, 737; dH (300 MHz; CDCl3) 11.75 (1 H, s, OH), 6.61 (1 H, s,
ArH), 6.21 (1 H, s, OH), 5.47–5.33 (3 H, m, CH=CH, OCHMe), 4.25 (2 H,
AB, J 17.7, ArCH2), 2.62–1.41 (10 H, m, 5 3 CH2), 1.39 (3 H, d, J 6.4,
Me); dC (75 MHz; CDCl3) 206.7, 170.0, 163.5, 156.1, 136.1, 135.2
(CH), 124.3 (CH), 114.6, 107.6, 103.5 (CH), 73.1 (CH), 46.7 (CH2),
41.0 (CH2), 37.6 (CH2), 32.4 (CH2), 25.2 (CH2), 22.0 (CH2), 18.8 (Me);
m/z (EI) 354/352 (M+, 6/16%), 183 (100).
(S)-1-Chloro-2,4-dihydroxy-7-methyl-7,8,11,12,13,14-
hexahydro-6-oxa-16H-benzocyclotetradecene-5,15-dione 15d
mp 131C 2133C; [a]23D + 16.0 (c 1.00, CHCl3); (Found: MH
+,
353.1159. C18H21
35ClO + H requires 353.1156); nmax (KBr)/cm
21
3320, 2934, 2856, 1704, 1651, 737; dH (300 MHz; CDCl3) 11.75 (1 H,
s, OH), 6.61 (1 H, s, ArH), 6.21 (1 H, s, OH), 5.47–5.33 (3 H, m,
CH=CH, OCHMe), 4.25 (2 H, AB, J 17.7, ArCH2), 2.62–1.41 (10 H,
m, 5 3 CH2), 1.39 (3 H, d, J 6.4, Me); dC (75 MHz; CDCl3) 206.7,
170.0, 163.5, 156.1, 136.1, 135.2 (CH), 124.3 (CH), 114.6, 107.6,
103.5 (CH), 73.1 (CH), 46.7 (CH2), 41.0 (CH2), 37.6 (CH2), 32.4 (CH2),
25.2 (CH2), 22.0 (CH2), 18.8 (Me); m/z (CI) 355/353 (M
+, 25/72%),
335 (100).
(R)-1-Chloro-2,4-dihydroxy-7-methyl-7,8,9,12,13,14-hexahydro-
6-oxa-16H-benzocyclotetradecene-5,15-dione 15e
mp 133C 2135C; (Found: M+, 352.1072. C18H21
35ClO5 requires
352.1078); nmax (KBr)/cm
21 3361, 2930, 1715, 1651, 730; dH (300
MHz; CDCl3) mixture of isomers 11.97 (1 H, s, OH), 11.86 (1 H, s,
OH), 6.60 (1 H, s, ArH), 6.57 (1 H, s, ArH), 6.30 (1 H, s, OH), 5.49–
5.02 (3 H, m, CH=CH, OCHMe), 4.76–4.01 (2 H, m, ArCH2), 2.61–
1.44 (10 H, m, 5 3 CH2) 1.39 (3 H, d, J 6.2, Me); dC (75 MHz; CDCl3)
mixture of isomers 205.8, 205.6, 170.5, 164.9, 163.7, 156.17,
156.12, 136.1, 135.6, 130.9 (CH), 130.7 (CH), 130.0 (CH), 128.4 (CH),
114.8, 107.2, 103.63 (CH), 163.60 (CH), 75.4 (CH), 74.3 (CH), 46.7
(CH2), 46.6 (CH2), 39.3 (CH2), 37.6 (CH2), 36.4 (CH2), 33.9 (CH2),
31.4 (CH2), 28.8 (CH2), 24.6 (CH2), 23.4 (CH2), 21.2 (CH2), 20.4 (Me),
19.8 (Me), 19.4 (Me); m/z (EI) 354/352 (M+, 4/12%), 284 (12), 183
(90), 55 (100).
(Z)-1-Chloro-2,4-dihydroxy-8,11,12,13-tetrahydro-7H,15H-6-
oxabenzocyclotridecane-5,14-dione cis-15f
mp 164C2166C; (Found: MH+, 325.0838. C16H17ClO5 + H requires
325.0843); nmax (KBr)/cm
21 3333, 2923, 2854, 1693, 1667, 1313,
1231; dH (300 MHz; (CD3)2CO) 11.18 (1 H, s, OH), 9.77 (1 H, s, OH),
6.51 (1 H, s, ArH), 5.44–5.27 (2 H, m, CH=CH), 4.42 (2 H, s, OCH2),
4.08 (2 H, s, ArCH2), 2.47–2.36 (4 H, m, 2 3 CH2), 2.17–2.10 (2 H, m,
CH2), 1.70–1.62 (2 H, m, CH2); dC (75 MHz; (CD3)2CO) 207.2, 172.4,
164.1, 159.9, 138.6 (C) 133.1 (CH), 130.0 (CH), 116.8, 109.3, 104.5
(CH), 67.3 (CH2), 49.4 (CH2), 39.4 (CH2), 28.2 (CH2), 26.0 (CH2), 22.4
(CH2); m/z (CI) 327/325 (MH
+, 34/100%), 307 (90), 286 (56), 263 (26).
(E)-1-Chloro-2,4-dihydroxy-8,11,12,13-tetrahydro-7H,15H-6-
oxabenzocyclotridecane-5,14-dione trans-15f
mp 155C2157C; (Found: MH+, 325.0832. C16H17ClO5 + H requires
325.0843); nmax (KBr)/cm
21 3333, 2923, 2854, 1693, 1667, 1313,
1231; dH (300 MHz; (CD3)2CO) 11.41 (1 H, s, OH), 9.79 (1 H, s, OH),
6.67 (1 H, s, ArH), 5.56–5.32 (2 H, m, CH=CH), 4.60 (2 H, s, OCH2),
4.53 (2 H, s, ArCH2), 2.70–2.68 (2 H, m, CH2), 2.50–2.40 (2 H, m,
CH2), 2.44–2.18 (2 H, m, CH2), 2.08–1.92 (2 H, m, CH2); dC (75 MHz;
(CD3)2CO) 205.9, 172.4, 163.9, 159.6, 138.9 (C) 134.7 (CH), 129.1
(CH), 116.4, 109.6, 104.4 (CH), 66.1 (CH2), 48.7 (CH2), 42.7 (CH2),
35.5 (CH2), 34.0 (CH2), 22.3 (CH2); m/z (CI) 327/325 (MH
+, 34/
100%), 307 (43), 291 (24), 263 (12).
1-Chloro-2,4-dihydroxy-7,8,11,12-tetrahydro-14H-6-
oxabenzocyclododecene-5,13-dione 15g
mp 164C 2166C; (Found: M+, 310.0602. C15H15
35ClO5 requires
310.0608); nmax (KBr)/cm
21 3232, 2927, 2852, 1696, 1654, 1315,
1241; dH (300 MHz; (CD3)2CO) mixture of isomers 11.78 (1 H, s,
OH), 11.76 (1 H, s, OH), 9.73 (1 H, s, OH), 9.69 (1 H, s, OH), 6.52 (1
H, s, ArH), 5.71–5.29 (2 H, m, CH=CH), 4.48–4.25 (4 H, s, OCH2,
ArCH2), 2.60–2.30 (4 H, m, 2 3 CH2); dC (75 MHz; (CD3)2CO) mixture
of isomers 207.1, 205.7, 171.9, 163.9, 163.8, 158.7, 138.3 (C) 138.1,
132.0 (CH), 131.8 (CH), 130.0 (CH), 128.3 (CH), 115.8, 115.7, 107.8,
107.1, 103.6 (CH), 103.4 (CH), 66.6 (CH2), 66.1 (CH2), 50.7 (CH2),
48.4 (CH2), 42.9 (CH2), 41.6 (CH2), 32.2 (CH2), 26.7 (CH2), 25.0
(CH2); m/z (EI) 312/310 (12/42%), 185/183 (44/100).
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12121-Chloro-2,4-dihydroxy-8,11,12,13,14,15-hexahydro-7H,17H-6-
oxabenzocyclopentadecene-5,16-dione 15h
mp 129C 2131C; (Found: MH+, 353.1160. C18H21
35ClO5 + H re-
quires 353.1156); nmax (KBr)/cm
21 3272, 2935, 2860, 1688, 1238,
1115; dH (300 MHz; CDCl3) dH (300 MHz; CDCl3) major isomer 11.49
(1 H, s, OH), 6.57 (1 H, s, ArH), 6.36 (1 H, s, OH), 5.46–5.27 (2 H, m,
CH=CH), 4.42 (2 H, t, J 4.52, OCH2), 4.33 (2 H, s, ArCH2), 2.54–2.48
(2 H, m, CH2), 2.44–2.35 (2 H, m, CH2), 2.07–2.01 (2 H, m, CH2),
1.73–1.61 (2 H, m, CH2), 1.44–1.24 (4 H, m, 2 3 CH2); minor isomer
11.59 (1 H, s, OH), 6.56 (1 H, s, ArH), 6.38 (1 H, s, OH), 4.47 (2 H, t,
J 6.0, OCH2); dC (75 MHz; CDCl3) mixture of isomers 207.9, 170.9,
163.5, 156.6, 136.4 (C) 133.4 (CH), 127.8 (CH), 126.5 (CH), 114.7,
108.4, 104.0 (CH), 67.5 (CH2), 66.5 (CH2), 47.6 (CH2), 41.9 (CH2),
32.0 (CH2), 30.6 (CH2), 27.5 (CH2), 27.1 (CH2), 26.1 (CH2), 25.8
(CH2), 22.5 (CH2), 21.9 (CH2); m/z (CI) 355/353 (MH
+, 18/70%), 391
(53), 353 (75), 257 (100).
(R)-1-Chloro-2,4-dihydroxy-7-methyl-8,11,12,13,14,15-
hexahydro-7H,17H-6-oxabenzocyclopentadecene-5,
16-dione 15i
Colorless oil; (Found: MH+, 367.1315. C19H23
35ClO5 + H requires
367.1312); nmax(KBr)/cm
21 3522, 2934, 1712, 1656, 1602, 1308; dH
(400 MHz; CDCl3) mixture of isomers 6.59 (1 H, s, ArH), 6.43 (1 H, s,
OH), 5.50–5.34 (3 H, m, CH=CH, OCHMe), 4.41 (2 H, s, ArCH2),
2.67–2.59 (2 H, m, CH2), 2.46–2.38 (2 H, m, CH2), 2.33–1.45 (8 H, m,
4 3 CH2), 1.77 (3 H, d, J 6.3, Me), 1.45 (3 H, d, J 6.3, Me); dC (100
MHz; CDCl3) mixture of isomers 207.5, 160.7, 163.0, 156.1, 136.2,
134.2 (CH), 124.4 (CH), 114.4, 107.9, 103.7 (CH), 73.2 (CH), 46.9
(CH2), 40.9 (CH2), 37.2 (CH2), 29.7 (CH2), 25.8 (CH2), 25.2 (CH2),
21.6 (CH2), 18.8 (Me); m/z (ES) 391/389 ([M + Na]
+, 100/34%), 369/
367 (MH+, 30/10%), 349 (51).
1-Chloro-2,4-dihydroxy-7,8,11,12,13,14,15,16-octahydro-18H-6-
oxabenzocyclohexadecene-5,17-dione 15j
mp 158C 2160C; (Found: MH+, 367.1290. C19H23
35ClO5 + H re-
quires 367.1312); nmax (KBr)/cm
21 3519, 2928, 2855, 1717, 1660,
1311; dH (400 MHz; CDCl3) mixture of isomers 6.62 (1 H, s, ArH),
6.61 (1 H, s, ArH), 6.49 (1 H, s, OH), 6.23 (1 H, s, OH), 5.49–5.37 (2
H, m, CH=CH), 4.49–4.42 (4 H, s, OCH2), 4.30 (2 H, s, ArCH2), 2.59–
2.46 (4 H, m, 2 3 CH2), 2.11–2.05 (2 H, m, CH2), 1.72–1.64 (2 H, m,
CH2), 1.47–1.37 (4 H, m, 2 3 CH2), 1.27–1.19 (2 H, m, CH2); dC (100
MHz; CDCl3) mixture of isomers 206.0, 170.4, 163.5, 156.3, 136.1
(C) 133.3 (CH), 132.8 (CH), 127.0 (CH), 114.9, 107.3, 103.6 (CH),
68.4 (CH2), 67.8 (CH2), 47.0 (CH2), 46.7 (CH2), 39.7 (CH2), 31.7
(CH2), 29.9 (CH2), 26.2 (CH2), 25.7 (CH2), 24.4 (CH2), 21.9 (CH2); m/z
(CI) 369/367 (MH+, 25/100%), 349 (22), 333 (16).
(E)-1-Chloro-9,10-epoxy-2,4-dihydroxy-7,8,11,12,13,14-
hexahydro-6-oxa-16H-benzocyclotetradecene-5,15-dione 16a
Colorless oil; (Found: M+, 354.0850. C17H19
35ClO6 requires
354.0870); nmax (film)/cm
21 3370, 2927, 2856, 1713, 1658, 1237; dH
(300 MHz; (CD3)2CO) 11.24 (1 H, s, OH), 9.68 (1 H, s, OH), 6.42 (1 H,
s, ArH), 4.54–4.06 (4 H, m, 2 3 CH2), 2.78–0.65 (12 H, m, 5 3 CH2, 2
3 CH); dC (75 MHz; CDCl3) 206.9, 171.8, 163.7, 159.2, 138.0, 116.3,
108.5, 104.1 (CH), 64.1 (CH2), 58.5 (CH), 57.6 (CH), 47.6 (CH2), 41.2
(CH2), 31.8 (CH2), 31.7 (CH2), 24.6 (CH2), 23.8 (CH2); m/z (FI) 356/
354 (M+, 35/100%), 268 (9).
1-Chloro-9,10-epoxy-2,4-dihydroxy-7-methyl-7,8,11,12,13,14-
hexahydro-6-oxa-16H-benzocyclotetradecene-5,15-dione 16b
Colorless oil; (Found: M+, 368.1000. C18H21
35ClO2 requires 368.1027);
nmax(film)/cm
21 3328, 2931, 1711, 1650, 1240, 731; dH (300 MHz;
CDCl3) major isomer 11.55 (1 H, s, OH), 6.64 (1 H, s, ArH), 6.17 (1 H,
s, OH), 5.36–5.27 (1 H, m, OCHMe), 4.30 (2 H, AB, J 17.9, ArCH2),
2.82–2.77 (1 H, m, CH(O)), 2.67–2.63 (1 H, m, CH(O)), 2.53–2.46 (2 H,
m, CH2), 2.33–1.23 (8 H, m, 43 CH2), 1.48 (3 H, 2 d, J 6.4, Me); minor
isomer 11.34 (1 H, s, OH), 6.63 (1 H, s, ArH), 5.52–5.42 (1 H, m,
OCHMe), 4.40 (2 H, AB, J 17.9, ArCH2), 1.43 (3 H, 2 d, J 6.4, Me); dC
(75 MHz; CDCl3) mixture of diastereoisomers 205.8, 205.6, 169.1,
162.9, 155.6, 135.0, 114.2, 106.8, 103.2 (CH), 71.4 (CH), 70.8 (CH),
58.0 (CH2), 56.8 (CH2), 54.4 (CH2), 54.2 (CH2), 46.3 (CH2), 46.0 (CH2),
40.0 (CH2), 39.5 (CH2), 36.8 (CH2), 35.7 (CH2), 30.4 (CH2), 28.9 (CH2),
22.7 (CH2), 22.1 (CH2), 21.6 (CH2), 21.3 (CH2), 20.0 (Me), 18.4 (Me);
m/z (FI) 370/368 (M+, 41/100%), 290 (13), 202 (3).
1-Chloro-2,4-dihydroxy-7-methyl-7,8,9,10,11,12,13,14-
octahydro-6-oxa-16H-benzocyclotetradecene-5,15-dione 17
mp 154C 2156C; (Found: M+, 354.1243. C18H23
35ClO5 requires
354.1234); nmax (KBr)/cm
21 3437, 2931, 2835, 1703, 1645, 668; dH(300 MHz; CDCl3) 11.85 (1 H, s, OH), 6.73 (1 H, s, OH), 6.50 (1 H, s,
ArH), 5.19–5.09 (1 H, m, OCHMe), 4.55 (2 H, AB, J 18.2, ArCH2),
2.85–2.51 (2 H, m, CH2), 1.95–0.87 (12 H, m, 6 3 CH2), 1.48 (3 H, d,
J 6.0, Me); dC (75 MHz; CDCl3) 207.1, 170.5, 163.5, 156.4, 135.6,
114.9, 107.2, 103.8 (CH), 74.5 (CH), 46.8 (CH2), 39.7 (CH2), 34.8
(CH2), 26.4 (CH2), 23.6 (CH2), 23.2 (CH2), 22.2 (CH2), 21.8 (CH2),
20.8 (Me); m/z (FI) 356/354 (M+, 34/100%).
1,3-Dibromo-2,4-dihydroxy-8,11,12,13,14,15-hexahydro-7H,17H-
6-oxabenzocyclopentadecene-5,16-dione 18
Colorless oil; (Found: MH+, 474.9742. C18H20
79Br2O5 + H requires
474.9731); nmax (CHCl3)/cm
21 3476, 2926, 2854, 1711, 1658, 1306;
dH (400 MHz; CDCl3) mixture of isomers 6.50 (1 H, s, OH), 5.51–5.40
(2 H, m, CH=CH), 4.54–4.42 (4 H, s, ArCH2, COCH2), 2.58–2.52 (2 H,
m, CH2), 2.46–2.42 (2 H, m, CH2), 2.10–2.06 (2 H, m, CH2), 1.74–
1.27 (6 H, m, 3 3 CH2); dC (100 MHz; CDCl3) mixture of isomers
206.4, 170.5, 159.7, 154.0, 137.2 (C) 133.1 (CH), 127.2 (CH), 108.8,
105.6, 98.3, 67.9 (CH2), 66.8 (CH2), 49.9 (CH2), 49.6 (CH2), 41.8
(CH2), 41.7 (CH2), 31.6 (CH2), 30.1 (CH2), 27.0 (CH2), 26.7 (CH2),
25.7 (CH2), 25.6 (CH2), 22.7 (CH2), 21.5 (CH2); m/z (CI) 474/476/478
(MH+, 41/100/36%).
(R)-Pent-4-en-2-yl 3-chloro-4,6-dihydroxy-2-(2-oxo-oct-7-
enyl)benzoate 19
Colorless oil; [a]23D 2 26.0 (c 1.00, CHCl3); (Found: M
+, 380.1389.
C20H25
35ClO5 requires 380.86); nmax (film)/cm
21 3262, 3077, 2933,
1652, 1433, 1244; dH (300 MHz; CDCl3) 11.38 (1 H, s, OH), 6.54 (1 H,
s, ArH) 6.44 (1 H, s, OH), 5.85–5.67 (2 H, m, 2 3 CH=CH2), 5.33–
5.23 (1 H, m, OCHMe), 5.16–4.92 (4 H, m, 2 3 CH=CH2), 4.27 (2 H,
AB, J 17.9, ArCH2), 2.48 (2 H, t, J 7.3, CH2), 2.42–2.33 (2 H, m,
CH2), 2.10–2.03 (2 H, m, CH2), 1.69–1.61 (2 H, m, CH2), 1.45–1.35 (2
H, m, CH2), 1.30 (3 H, d, J 6.4, Me); dC (75 MHz; CDCl3) 206.5,
169.2, 163.0, 156.2, 138.3 (CH), 135.7, 132.9 (CH), 118.6 (CH2),
114.7 (CH2), 107.5, 103.6 (CH), 72.6, 47.0 (CH2), 41.8 (CH2), 40.0
(CH2), 33.5 (CH2), 28.3 (CH2), 23.0 (CH2), 19.4 (Me); m/z (EI) 382/380
(M+, 2/7%), 294 (10), 183 (100).
1-Chloro-2,4-dimethoxy-7-methyl-7,8,11,12,13,14-hexahydro-6-
oxa-16H-benzocyclotetradecene-5,15-dione 25
Colorless oil; (Found: M+, 380.1382. C20H25
35ClO5 requires
380.1391); nmax (film)/cm
21 2936, 2846, 1721, 1592; dH (300 MHz;
CDCl3) 6.47 (1 H, s, ArH), 5.45–5.39 (2 H, m, CH=CH), 5.22–5.11 (1
H, m, OCHMe), 3.91 (3 H, s, Me), 3.84 (3 H, s, Me), 3.83 (2 H, AB, J
17.3, ArCH2), 2.43–1.38 (10 H, m, 5 3 CH2), 1.36 (3 H, d, J 6.3,
Me); dC (75 MHz; CDCl3) 206.5, 167.0, 156.5, 156.4, 134.1 (CH),
132.7, 126.0 (CH), 118.5, 115.4, 95.5 (CH), 72.3 (CH), 56.2 (Me),
56.1 (Me), 45.1 (CH2), 40.9 (CH2), 38.8 (CH2), 31.8 (CH2), 25.9 (CH2),
23.0 (CH2), 20.0 (Me); m/z (FI) 382/380 (M
+, 35/100%), 366 (11),
346 (3).
1-Chloro-9,10-epoxy-2,4-dimethoxy-7-methyl-7,8,11,12,13,14-
hexahydro-6-oxa-16H-benzocyclotetradecene-5,15-dione 26
Colorless oil; (Found: M+, 396.1333. C20H25
35ClO6 requires
396.1340); nmax (film)/cm
21 2932, 2850, 1714, 1604, 1261, 812; dH
(300 MHz; CDCl3) mixture of diastereomers 6.58–6.45 (1 H, m,
ArH), 5.39–5.00 (2 H, m, CH2), 4.24–3.56 (8 H, m, ArCH2, 2 3 Me),
2.78–1.17 (12 H, m, 5 3 CH2, 2 3 CH), 1.36 (3 H, d, J 6.3, Me); dC
(75 MHz; CDCl3) mixture of diastereomers 206.2, 205.2, 166.2,
155.8, 155.3, 132,3, 131.3, 116.75, 114.5, 94.5 (CH), 69.7 (CH), 69.4
(CH), 60.68 (CH), 58.08 (CH), 57.5 (CH), 56.6 (CH), 55.4 (Me), 55.2
(Me), 55.1 (Me), 54.5 (CH), 43.6 (CH2), 43.5 (CH2), 40.5 (CH2), 39.7
(CH2), 37.8 (CH2), 36.6 (CH2), 29.6 (CH2), 28.9 (CH2), 28.6 (CH2),
23.7 (CH2), 22.9 (CH2), 22.5 (CH2), 21.6 (CH2), 19.7 (Me), 18.8 (Me);
m/z (FI) 398/396 (M+, 23/100%).
Modeling
Molecular modeling was performed by using the Dock function in
MOE (MOE 2004.03, Chemical Computing Group Inc., Cambridge,
UK). In MOE-Dock, the configuration space includes all orientations
and conformations of the ligand such that all of its atoms are inside
the docking box.
Small-Molecule Crystallography
The atomic coordinates for compounds 14b, 14f, 15g, and 23 have
been deposited with the Cambridge Crystallographic Data Centre.
The coordinates can be obtained upon request from The Director,
Cambridge Crystallographic Data Centre, 12 Union Road, Cam-
bridge, CB2 1EZ, United Kingdom.
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The expression, purification, and crystallization of the N-terminal
domain of yeast Hsp90 have been previously described [62]. Coc-
rystallizations were conducted by dissolving the inhibitor in 100%
DMSO at 50 mM and by adding 5 ml of this solution to 1 ml of the
N-terminal domain of Hsp90 at 4 mg ml21 in 20 mM Tris (pH 7.5)
and 1 mM EDTA. The complex was then concentrated to 200 ml (20
mg ml21) and was crystallized as previously described [62]. Single
crystals of approximate dimensions 0.3 3 0.2 3 0.2 mm appeared
overnight. These were flash frozen after stepwise addition of glyc-
erol to 30%, and data were collected on station ID23.1 and ID23.2
at the European Synchrotron Radiation Facility. The data were inte-
grated by using MOSFLM and were scaled and merged with SCALA
in CCP4.
The complex was initially solved by isomorphous replacement by
using a previously determined N-terminal structure (PDB ID: 1AH6)
in the usual space group, P4322. The model was refined in REFMAC5
in CCP4 and was rebuilt with COOT. The Rfree value did not refine be-
low 30%; thus, other space groups were investigated. Refinement
proceeded satisfactorily in C2, with four molecules in the asymmet-
ric unit. The inhibitor library was built with SKETCHER. The inhibitor
molecule and the waters were added in the final stages.
Biology
FP Assay
This is a measurement of binding competition with a fluorescent
probe as described previously [33, 61].
Malachite Green Assay
A colorimetric assay for the release of inorganic phosphate upon hy-
drolysis of ATP was used to determine the potency of Hsp90 inhib-
itors against the enzyme. It is based on the formation of the phos-
phomolybdate complex and the subsequent reaction with
malachite green [60].
Growth Inhibition Assay
The colorimetric sulforhodamine B assay (SRB) was used to mea-
sure growth inhibition as described previously [63]. The IC50 was cal-
culated as the drug concentration that inhibits cell growth by 50%
compared with control growth.
Western Blotting
HCT116 cells were treated with 5 3 IC50 of selected compounds for
24 and 48 hr. Client proteins were immunoblotted and detected by
enhanced chemiluminescence [63]. Antibody to Hsp70 was pur-
chased from Stressgen Biotechnologies (Victoria, Canada); those
for C-RAF, CDK4, and ERBB2 were purchased from Santa Cruz
(CA, USA), and GAPDH was purchased from Chemicon (Hampshire,
UK).
Isothermal Titration Calorimetry
Yeast Hsp90 was dialyzed against 20 mM Tris (pH 7.5) containing 1
mM EDTA and 5 mM NaCl; it was then diluted to 8 mM in the same
buffer, but containing 2% DMSO. Compounds were dissolved in
100% DMSO at a concentration of 50 mM and were subsequently di-
luted to 100 mM in the same buffer as for Hsp90 (with 2% DMSO).
Heats of the interaction were measured at 30C on an MSC system
(Microcal), with a cell volume of 1.458 ml. Ten aliquots of 27 ml of 100
mM compound were injected into 8 mM yeast Hsp90. Heats of dilution
were determined in a separate experiment by injecting compound
into buffer containing 2% DMSO, and the corrected data were fit
with a nonlinear least square curve-fitting algorithm (Microcal Origin)
with three floating variables: stoichiometry, binding constant, and
change in enthalpy of interaction.
Supplemental Data
Supplemental Data include full experimental details and the charac-
terization data for all intermediates and are available at http://www.
chembiol.com/cgi/content/full/13/11/1203/DC1/.
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